Silence Therapeutics (LON:SLN) Sets New 1-Year High at $330.00

Silence Therapeutics plc (LON:SLN) reached a new 52-week high on Thursday . The stock traded as high as GBX 330 ($4.31) and last traded at GBX 324 ($4.23), with a volume of 281743 shares changing hands. The stock had previously closed at GBX 314 ($4.10).

Separately, Peel Hunt reissued a “buy” rating on shares of Silence Therapeutics in a report on Tuesday, September 24th.

The company has a market cap of $253.78 million and a price-to-earnings ratio of -12.81. The company has a fifty day moving average of GBX 210.56 and a two-hundred day moving average of GBX 129.75.

In other news, insider Dave Lemus acquired 4,000 shares of the business’s stock in a transaction that occurred on Friday, October 4th. The shares were bought at an average price of GBX 186 ($2.43) per share, with a total value of £7,440 ($9,721.68). Also, insider Steven Romano acquired 10,000 shares of the business’s stock in a transaction that occurred on Wednesday, October 2nd. The shares were purchased at an average cost of GBX 193 ($2.52) per share, for a total transaction of £19,300 ($25,218.87).

Silence Therapeutics Company Profile (LON:SLN)

Silence Therapeutics plc focuses on the discovery, development, and delivery of novel RNA therapeutics. The company designs short interfering RNA (siRNA) molecules that trigger the RNAi pathway and mediate the degradation of specific target messenger RNAs. It is developing various candidates for the treatment of cancer, iron overload disorders, cardiovascular disease, alcohol use disorder, and other metabolic diseases.

Featured Story: What is the return on assets formula?

Receive News & Ratings for Silence Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silence Therapeutics and related companies with's FREE daily email newsletter.